retatrutide hfpef trial Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes RAPID-HF Trial

doi: 10.1006/abbi.2001.2313

- ,

In it, the researchers administered MOTS-c to mice at various life stages young (two months old), middle-aged (12 months old), and old (22 months old) and saw that subjects at every life stage exhibited improved physical performance in multiple tests, including those assessing motor coordination and running capacity.21 The findings arent dissimilar to a 2023 study in humans, which found that a higher serum MOTS-c concentration correlated with greater muscle mass, force, and power generated during jumping in healthy subjects.22 Reduced inflammation A 2024 study on mature mice points to MOTS-cs potential as a treatment for acute and chronic inflammatory disorders

ACS Omega 4(1):961970

However, its crucial to consult with a healthcare professional before starting any peptide therapy to ensure safe and effective use